MAM
ENTA icon

Martingale Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Martingale Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
23,778
+7,226
+44% +$97.1K 0.01% 727
2026
Q1 		$209K Buy
+16,552
New +$222K 0.01% 774
2023
Q3 		– Sell
-21,865
Closed -$468K – 799
2023
Q2 		$468K Buy
21,865
+501
+2% +$14.8K 0.01% 628
2023
Q1 		$864K Buy
21,364
+501
+2% +$23.9K 0.02% 481
2022
Q4 		$971K Buy
20,863
+3,706
+22% +$169K 0.02% 463
2022
Q3 		$891K Buy
17,157
+1,451
+9% +$84.8K 0.02% 475
2022
Q2 		$743K Buy
15,706
+300
+2% +$16.3K 0.01% 546
2022
Q1 		$1.1M Buy
15,406
+100
+0.7% +$6.51K 0.02% 459
2021
Q4 		$1.15M Sell
15,306
-15,152
-50% -$1.19M 0.01% 457
2021
Q3 		$1.73M Buy
30,458
+11,050
+57% +$546K 0.02% 351
2021
Q2 		$855K Hold
19,408
– – 0.01% 442
2021
Q1 		$958K Buy
19,408
+1,399
+8% +$69.8K 0.01% 437
2020
Q4 		$759K Sell
18,009
-22,899
-56% -$1.01M 0.01% 517
2020
Q3 		$1.87M Buy
40,908
+31,206
+322% +$1.51M 0.02% 440
2020
Q2 		$488K Buy
+9,702
New +$502K 0.01% 881

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Martingale Asset Management's ENTA Position: Q2 2026 in Review

Martingale Asset Management increased its Enanta Pharmaceuticals (ENTA) stake by 44% in Q2 2026, buying an estimated $97.1K and bringing the position to 23,778 shares worth $347K. The position accounts for 0.01% of the portfolio, ranked #727.

Martingale Asset Management first reported a position in ENTA in Q2 2020 and has held it in 15 quarters since. The position peaked at $1.87M in Q3 2020. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Martingale Asset Management held 23,778 shares of Enanta Pharmaceuticals worth $347K as of Q2 2026.
  • Martingale Asset Management bought 7,226 Enanta Pharmaceuticals shares in Q2 2026, an estimated $97.1K.
  • Enanta Pharmaceuticals made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #727 holding.
  • Martingale Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • Martingale Asset Management's Enanta Pharmaceuticals position peaked at $1.87M in Q3 2020.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.